On May 11, 2022, Kaiser Permanente Washington Health Research Institute reported that new treatments for people at high risk for severe COVID-19 appear to be a good value.

All treatments were better than placebo at preventing hospitalization or death. The groups treated with a drug had up to an 88% lower risk of one of these outcomes than the groups given placebo. Paxlovid showed the greatest reduction in relative risk of hospitalization or death from any cause compared to placebo.